Innovations by Precisio Biotix Therapeutics in Treating Infections
Precisio Biotix Therapeutics announced the continuation of its expanded access program, with dosing of a staph lysin called ClyO (LYSG101) to a patient with chronic prosthetic joint infection.
With its commitment to research, Precisio Biotix Therapeutics continues to explore new methods to tackle challenging infections.
Precisio Biotix Therapeutics is dedicated to advancing treatment options for patients suffering from severe infections and is at the forefront of innovative therapies.
Dr. Raymond Schuch, VP, Director of US Operations, notes “Precisio’s ability to discover and then uniquely engineer potent lysins for human medicinal use without causing resistance, places us at the forefront of a revolution in precision antimicrobial therapies to target infections and diseases in which antibiotics fail and alternatives are diminishing.
The innovative strategies of Precisio Biotix Therapeutics highlight the importance of precision medicine in today’s healthcare landscape.
Mark Engel, Founder and CEO of Precisio said “Knee and hip replacements are soaring in the US and globally, bringing with them an increasing incidence of prosthetic joint infections.
With the support of the company, patients are receiving groundbreaking therapies that change the course of their treatment.
Overall, Mr. Engel summarizes that “The engineered lysins we are developing, that do not cause antibiotic resistance, will have a tremendous impact.